{"entity":{"id":"palacaparib","kind":"drug","name":"Palacaparib","aka":[],"tldr":"Palacaparib is an experimental small-molecule drug from AstraZeneca in phase 2 trials for ovarian cancer, non-small-cell lung cancer and endometrial cancer, aimed at PARP.","summary":"Palacaparib (AZD9574) is a small-molecule drug developed by AstraZeneca. Its target is PARP (the sponsor names PARP). The sponsor states: An oral PARP inhibitor that blocks PARP enzyme activity, preventing DNA repair in cancer cells, particularly tumours with homologous recombination deficiency. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in ovarian cancer, non-small-cell lung cancer and endometrial cancer. The largest, NCT05797168, plans to enrol 602 participants with primary completion expected 2028-08-04. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Palacaparib","url":"https://clinicaltrials.gov/search?intr=AZD9574"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian","nsclc","endometrial"],"sections":[],"technologies":[],"targets":["parp"],"drugs":[],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07181161","nct05797168","nct05123482","nct07590934","nct05417594"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"AZD9574","modality":"small molecule","mechanism":"An oral PARP inhibitor that blocks PARP enzyme activity, preventing DNA repair in cancer cells, particularly tumours with homologous recombination deficiency.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/palacaparib/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"trial":[{"id":"nct05123482","kind":"trial","name":"A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies","route":"/trials/nct05123482/"},{"id":"nct05797168","kind":"trial","name":"Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors","route":"/trials/nct05797168/"},{"id":"nct07590934","kind":"trial","name":"Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer","route":"/trials/nct07590934/"},{"id":"nct07181161","kind":"trial","name":"Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer","route":"/trials/nct07181161/"},{"id":"nct05417594","kind":"trial","name":"Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies","route":"/trials/nct05417594/"}]}}